Want to see MANE full AI Analyst Report?
Top Page
Veradermics, Incorporated
(NYSE:MANE)
Select Model
Select Model
Rating:52Neutral
Price Target:
$107.00
▲(40.25% Upside)
Action:Reiterated
Date:07/17/26
The score is primarily held back by weak financial performance—no revenue, rapidly widening losses, accelerating cash burn, and a move to deeply negative equity—creating high funding risk. Technical indicators are mixed and do not show strong momentum. Offsetting these risks, recent corporate events are constructive, with both fresh capital raised and positive clinical data that could improve the outlook if subsequent studies and commercialization progress successfully.
Positive Factors
Positive Phase 2/3 efficacy and safety data
Demonstrated statistical efficacy and a favorable safety profile in a randomized Phase 2/3 cohort is durable proof-of-concept. This materially de-risks the clinical program, strengthens regulatory discussions, and improves prospects for partnerships, payer planning, and commercial development if replicated.
Negative Factors
Pre-revenue with accelerating losses and cash burn
The company generates no revenue and exhibited sharply widening losses and accelerating cash outflows, meaning operations depend on external funding. This persistent negative cash profile elevates dilution risk, constrains long-term planning, and pressures execution if financing conditions tighten.
Read all positive and negative factors
Positive Factors
Negative Factors
Positive Phase 2/3 efficacy and safety data
Demonstrated statistical efficacy and a favorable safety profile in a randomized Phase 2/3 cohort is durable proof-of-concept. This materially de-risks the clinical program, strengthens regulatory discussions, and improves prospects for partnerships, payer planning, and commercial development if replicated.
Read all positive factors
Veradermics, Incorporated (MANE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.37B
Dividend YieldN/A
Average Volume (3M)N/A
Price to Earnings (P/E)―
Beta (1Y)-0.58
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees21
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding41,778,687
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-10.94
Price to Sales (P/S)0.00
P/FCF Ratio-18.49
Enterprise Value/Market Cap0.84
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-75.59
Forecast
1Y Price Target
$169.20Price Target Upside121.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Veradermics, Incorporated Business Overview & Revenue Model
Company Description
Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (P...
Veradermics, Incorporated Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
22
Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -48.55M | -70.00M | -25.90M | -16.45M |
| Net Income | -49.08M | -70.00M | -26.49M | -16.49M |
Balance Sheet | ||||
| Total Assets | 398.58M | 152.62M | 59.38M | 18.46M |
| Cash, Cash Equivalents and Short-Term Investments | 390.80M | 141.86M | 53.08M | 16.30M |
| Total Debt | 0.00 | 4.00K | 0.00 | 786.00K |
| Total Liabilities | 6.72M | 273.63M | 4.72M | 3.84M |
| Stockholders Equity | 391.87M | -121.01M | 54.66M | 14.62M |
Cash Flow | ||||
| Free Cash Flow | -44.80M | -71.63M | -23.69M | -13.51M |
| Operating Cash Flow | -44.80M | -71.60M | -23.69M | -13.51M |
| Investing Cash Flow | -211.08M | -118.86M | 0.00 | 0.00 |
| Financing Cash Flow | 418.63M | 159.14M | 60.48M | 13.89M |
Veradermics, Incorporated Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | $6.10B | 69.48 | 13.65% | ― | 58.85% | 1646.61% | |
74 Outperform | $2.43B | 95.75 | 6.91% | ― | 22.95% | 228.76% | |
74 Outperform | $4.77B | 32.17 | 8.64% | ― | 17.28% | 323.64% | |
72 Outperform | $3.50B | -1,398.96 | -1.41% | ― | 95.29% | 98.21% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | $4.55B | -10.07 | 6.47% | ― | 100.51% | -10.99% | |
52 Neutral | $4.37B | -67.31 | -84.21% | ― | ― | ― |
* General Sector Average
MANE
Veradermics, Incorporated
105.00
67.25
178.15%
VCEL
Vericel
45.96
8.38
22.30%
VCYT
Veracyte
46.32
22.00
90.46%
KNSA
Kiniksa Pharmaceuticals
74.34
41.39
125.61%
ARQT
Arcutis Biotherapeutics
26.86
12.34
84.99%
CAI
Caris Life Sciences, Inc.
15.67
-13.82
-46.86%
Veradermics, Incorporated Corporate Events
Private Placements and Financing
Veradermics Boosts Capital Through Public Offering and Warrants
Positive
May 1, 2026
On May 1, 2026, Veradermics, Incorporated closed an underwritten public offering of 3,843,790 shares of common stock at $100.00 per share, and granted underwriters a 30-day option to purchase up to an additional 576,568 shares at the same price, l...
Business Operations and StrategyProduct-Related Announcements
Veradermics Reports Positive Phase 2/3 Data for VDPHL01
Positive
Apr 27, 2026
On April 27, 2026, Veradermics reported positive topline results from Part A of its Phase 2/3 Study 302 evaluating VDPHL01 in 519 men with mild-to-moderate pattern hair loss. The oral extended-release minoxidil met all primary and key secondary en...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.